Comparative efficacy and safety of different combinations of three CDK4/6 inhibitors with endocrine therapies in HR+/HER-2 − metastatic or advanced breast cancer patients: a network meta-analysis

Comparative efficacy and safety of different combinations of three CDK4/6 inhibitors with endocrine therapies in HR+/HER-2 − metastatic or advanced breast cancer patients: a network meta-analysis

Abstract Background This network meta-analysis aimed to assess the comparative efficacy and safety of combinations involving three cyclin-dependent kinase 4/6 (CDK4/6) inhibitors and endocrine therapies (ETs) in patients with metastatic or advanced breast cancer (BC) who are hormone receptor-positiv...

Full description

Bibliographic Details
Main Authors: Yiyuan Liu, Jinyao Wu, Zeqi Ji, Lingzhi Chen, Juan Zou, Jiehua Zheng, Weixun Lin, Jiehui Cai, Yaokun Chen, Daitian Zheng, Yexi Chen, Zhiyang Li
Format: Article
Language:English
Published: BMC 2023-08-01
Series:BMC Cancer
Subjects:
Breast cancer
Abemaciclib
Ribociclib
Palbociclib
Network meta-analysis
Online Access:https://doi.org/10.1186/s12885-023-11322-2

Internet

https://doi.org/10.1186/s12885-023-11322-2

Similar Items